Progyny, Inc. (NASDAQ:PGNY - Get Free Report) Chairman David J. Schlanger sold 71,272 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the sale, the chairman now owns 86,312 shares of the company's stock, valued at $3,262,593.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Progyny Stock Performance
Shares of Progyny stock opened at $38.15 on Friday. The firm has a 50-day simple moving average of $37.94 and a two-hundred day simple moving average of $35.63. The company has a market cap of $3.68 billion, a P/E ratio of 61.53, a price-to-earnings-growth ratio of 1.57 and a beta of 1.48. Progyny, Inc. has a fifty-two week low of $29.44 and a fifty-two week high of $44.95.
Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million during the quarter, compared to the consensus estimate of $274.08 million. During the same quarter in the prior year, the firm earned $0.03 EPS. The company's revenue for the quarter was up 26.0% on a year-over-year basis. Equities research analysts forecast that Progyny, Inc. will post 0.7 EPS for the current year.
Institutional Trading of Progyny
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
Several large investors have recently bought and sold shares of PGNY. Gotham Asset Management LLC acquired a new stake in Progyny during the 3rd quarter worth approximately $1,116,000. Northern Trust Corp lifted its holdings in Progyny by 1.3% during the 3rd quarter. Northern Trust Corp now owns 1,166,806 shares of the company's stock worth $39,695,000 after buying an additional 15,208 shares in the last quarter. Invesco Ltd. lifted its holdings in Progyny by 67.0% during the 3rd quarter. Invesco Ltd. now owns 888,427 shares of the company's stock worth $30,224,000 after buying an additional 356,529 shares in the last quarter. Deutsche Bank AG lifted its holdings in Progyny by 12.7% during the 3rd quarter. Deutsche Bank AG now owns 42,029 shares of the company's stock worth $1,430,000 after buying an additional 4,738 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Progyny by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 630,648 shares of the company's stock valued at $21,455,000 after purchasing an additional 46,144 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on PGNY shares. SVB Leerink initiated coverage on Progyny in a research note on Monday, February 26th. They issued an "outperform" rating and a $49.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. Truist Financial dropped their target price on shares of Progyny from $47.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, February 28th. KeyCorp dropped their target price on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday, February 28th. Finally, Barclays began coverage on shares of Progyny in a report on Wednesday, January 3rd. They issued an "overweight" rating and a $48.00 target price for the company. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Progyny presently has an average rating of "Buy" and a consensus target price of $48.30.
Get Our Latest Analysis on PGNY
About Progyny
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
